MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
WARREN, N.J., Feb. 03, 2016 -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it will participate in LEERINK Partners 5th Annual Global Healthcare Conference.
Jonathan Peacock, Bellerophon’s Chairman and Chief Executive Officer, will take questions during a fireside chat at 10:40 am ET on Wednesday, February 10, 2016.
A live webcast may be accessed under the investor tab at www.bellerophon.com. An archive of the presentation will be available following the presentation.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. The Company is currently developing two product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery device. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company intends to commence Phase 3 clinical trials shortly and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), which is in Phase 2 development. The Company is also planning to start testing the benefits of INOpulse for patients suffering from pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) for which results are anticipated by the end of 2016. For more information, please visit www.bellerophon.com.
Contact At Bellerophon: Amy Edmonds, Vice President Head of Clinical Operations & Administration (908) 574-4765 At Rx Communications Group: Melody Carey (917) 322-2571 [email protected]
